Skip to main content
. 2021 Apr 15;11(13):6293–6314. doi: 10.7150/thno.57177

Table 3.

Innate characteristics of common antibody platforms used in radiopharmaceutical development categorized as either engineered or enzymatically produced

Enzymatic Engineered
graphic file with name thnov11p6293i001.jpg graphic file with name thnov11p6293i002.jpg graphic file with name thnov11p6293i003.jpg graphic file with name thnov11p6293i004.jpg graphic file with name thnov11p6293i005.jpg graphic file with name thnov11p6293i006.jpg graphic file with name thnov11p6293i007.jpg graphic file with name thnov11p6293i008.jpg
Format Intact F(ab')2 Fab scFv-Fc Minibody Diabody scFv Nanobody
MW (kDa) 150 110 55 105 80 55 28 12-15
Valency Divalent Bivalent Monovalent Bivalent Bivalent Bivalent Monovalent Monovalent
Serum Half-life 1-3 weeks 125 8-10 h 125 12-20 h 125 8-80 h 126 (Terminal) 5-10 h 125 5-6 h 125 2-4 h 125 0.5-1 h 125
Clearance Route Liver 127 Liver, Kidney 123,127 Kidney 127 Liver Liver 127 Kidney 127 Kidney 127 Kidney 124